SignatureFD’s Insight Molecular Diagnostics IMDX Stock Holding History

SignatureFD’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6	Closed	-$1K	–	3162
2021 Q2	$1K	Buy	+6	New	+$586	﹤0.01%	2789

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SignatureFD's IMDX Position: Q3 2021 in Review

SignatureFD sold out of Insight Molecular Diagnostics (IMDX) in Q3 2021, closing a stake of 6 shares — an estimated $1K sold.

SignatureFD first reported a position in IMDX in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 95 funds tracked by Wall St. Rank hold IMDX as of Q3 2021.

SignatureFD reported no remaining Insight Molecular Diagnostics position as of Q3 2021 after selling out during the quarter.
SignatureFD sold 6 Insight Molecular Diagnostics shares in Q3 2021, an estimated $1K.
SignatureFD first reported a position in Insight Molecular Diagnostics in Q2 2021 and held it in 1 quarter.
SignatureFD's Insight Molecular Diagnostics position peaked at $1K in Q2 2021.
95 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2021.

Based on SignatureFD's 13F filing for Q3 2021, filed 28 Oct 2021.